HER2

Onco_background

Oncology Weekly News - September 15th 2025

Oncology Update : Ozuriftamab Phase 3, Libtayo 5-Year Data, INLEXZO Approval…

by LucidQuest

Onco_background

Oncology Weekly News - September 1st 2025

🔬🧬 Oncology Updates: Tevimbra EU Approval, KRAS G12C Fast Tracks, HER2-Low…

by LucidQuest

Onco_background

Oncology Weekly News - July 21st 2025

🔬🧬 Oncology Updates: Cue’s 50% ORR, ENHERTU’s New Designation, Kisqali’s UK Nod…

by LucidQuest

Onco_background

Oncology Weekly News - June 2nd 2025

🔬🧬 Oncology Updates: TEVIMBRA Advances, HER2+ Breakthroughs, and Global Cancer…

by LucidQuest

Onco_background

Oncology Weekly News - May 19th 2025

Latest breakthroughs in oncology research: FDA and EU Approvals, Key Trial Wins…

by LucidQuest

Onco_background

Oncology Weekly News - May 5th 2025

🧬🚀 Latest breakthroughs in oncology research! 🏥✨ From innovative trial results…

by LucidQuest

Onco_background

Oncology Weekly News - April 28th 2025

🧬🚀 Oncology Breakthroughs You Can’t Miss: From groundbreaking survival data to…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.